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Progressive diseaseMultiple sclerosis (MS) is a chronic inﬂammatory disease of the central nervous system which responds to
anti-inﬂammatory treatments in the early disease phase. However, the pathogenesis of the progressive
disease phase is less well understood, and inﬂammatory as well as neurodegenerative mechanisms of tissue
damage are currently being discussed. This review summarizes current knowledge on the interrelation
between inﬂammation, demyelination, and neurodegeneration derived from the study of human autopsy
and biopsy brain tissue and experimental models of MS.y, University Medical Centre,
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Multiple sclerosis (MS) is an inﬂammatory demyelinating CNS
disease frequently starting in young adulthood. Supported by
experimental evidence mainly derived from its principal model,
experimental allergic encephalomyelitis (EAE), MS is generally
considered a predominantly T cell-mediated autoimmune disease
[1]. In line with this notion, immunomodulatory and anti-inﬂamma-
tory therapies prove to be effective, especially early in the disease
phase. However, the disease often progresses relentlessly in later
disease stages without much imaging evidence for acute inﬂamma-
tion and no obvious effect of anti-inﬂammatory therapies. In addition,
substantial atrophy and loss of neuron-speciﬁc amino acids, such as
N-acetyl-aspartate (NAA), are already detectable early in the disease
[2]. As MS etiology still remains unknown, the above mentioned
ﬁndings raise the question of the interrelation between acute
inﬂammatory damage to CNS structures and early as well as late
stage damage to CNS tissue, especially to neurons and axons,
commonly termed “neurodegeneration”. Furthermore, the type of
inﬂammation that prevails in the chronic disease phase and its
effect on the target tissue is not well understood [3]. In addition,
the recent identiﬁcation of an astrocytic target of the immune
reaction in a disease closely resembling MS, namely neuromyelitis
optica (NMO), raises the question of whether the target structurein MS is necessarily the myelin sheath or oligodendrocyte [4]. This
review summarizes current knowledge and recent advances in MS
immunopathology.
2. Inﬂammation and demyelination
MS lesions can arise anywhere in the CNS. However, they show a
predilection for the optic nerve, spinal cord, brain stem, and
periventricular areas. Furthermore, brain tissue immediately adja-
cent to the subarachnoid space, i.e. subpial gray matter, is especially
vulnerable to demyelination [5], a fact that has only recently been
appreciated. Mostly, within a patient, lesions of similar age
resemble each other with respect to the extent and pattern of
inﬂammation and remyelination [6–8]. Mild meningeal inﬂamma-
tion consisting of T and B lymphocytes, plasma cells and macro-
phages is common [9].
2.1. Chronic MS lesions
The most common lesion types found at brain autopsy in patients
with long-standing MS are chronic hypocellular demyelinated lesions
with or without a variable extent of newly formed, thin myelin ﬁbers
at the edge, representing remyelination. With smaller lesions, their
perivascular, or Dawson ﬁnger location, is often apparent. Single
perivascular T cells are the rule. Few if any mature oligodendrocytes
are detected; oligodendrocyte precursor cells are present, however
scarce [10,11]. Axonal loss is often substantial and may reach around
70% compared to the normal appearing white matter (NAWM)
[12,13]. In contrast, little “acute” axonal damage is detected when
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amyloid precursor protein (APP). Reactive astrocytes may still be
present at the lesion border; more prominent, however, is a dense,
ﬁbrous gliosis. Vessels are often markedly hyalinised within chronic,
hypocellular demyelinated lesions.
In contrast to these seemingly inert lesions, scattered macro-
phages digesting myelin products may be present at the lesion edge,
mostly accompanied by scattered perivascular and parenchymal T
cells, indicating ongoing myelin destruction. Accordingly, signs of
axonal damage are routinely found at the edge of slowly expanding
lesions. It has been proposed that they are a pathological correlate of
disease progression [14,15]. It is unclear so far what underlies the
ongoing disease process in these lesions. In general, T cell
lymphocytic inﬁltration decreases over time and is markedly
reduced in late stage MS [9]. Additionally, these slowly expanding
lesions can still be found after autologous bone marrow transplan-
tation, suggesting that they are mainly driven by a CNS-resident
immune response [16].
2.2. Early MS lesions
Early MS lesions are more likely to be encountered in patients who
have been biopsied for reasons of differential diagnosis, but may also
be found at autopsy, especially in patients dying early in the disease
course [6,17]. The most studied lesions are “early active demyelinat-
ing” MS lesions where macrophages ﬁlled with minor, i.e. low
abundance myelin proteins, such as myelin oligodendrocyte glyco-
protein (MOG), cyclic nucleotide phosphodiesterase (CNPase) and
myelin-associated glycoprotein (MAG) cover most or part of the
lesion area [6]. The search for the “pre-lesion” has yielded areas of
extensive oligodendrocyte apoptosis with microglia activation, but no
dominant T cell inﬁltration or phagocytic macrophages [17]. It is
unclear so far what determines the site of lesion location, but vascular
factors are thought to play a role [18]. In addition to the dense
inﬁltration by foamy macrophages expressing markers of early
activation, such as MRP14 [19], early MS lesions are characterized
by a variable density of perivascular and parenchymal T lymphocyte
inﬁltration, and usually few B and plasma cells. In routine LFB/PAS
staining or immunohistochemistry for myelin proteins, early MS
lesions mostly appear pale, but not (yet) completely devoid of myelin.
Oligodendroglial cells are present in the lesions, often displaying an
activated phenotype with signs of early remyelination [20–22].
Axonal transport deﬁcits, as demonstrated e.g. by amyloid precursor
protein (APP) immunohistochemistry, are abundant throughout the
lesion [23–25].
2.3. Heterogeneity of early MS pathology
MS pathology in recent years has predominantly focussed on early,
actively demyelinating lesions and possible heterogeneous mechan-
isms of demyelination [6]. Studies based on a large set of biopsied
patients with inﬂammatory demyelinating lesions suggest that a
subset of patients displays antibody- and complement-mediated
mechanisms of demyelination, whereas lesions from a subset of other
patients show oligodendrocyte apoptosis as the probable cause of
myelin decay [6]. In around 50% of patients, immunoglobulin and
complement deposits are found in the lesions (pattern II), whereas
the rest are mainly distributed among patients with an “immune-
type” pattern of MS without complement deposition (pattern I) and
cases with oligodendrocyte apoptosis (pattern III). Few autopsy cases
so far were identiﬁed with dying oligodendrocytes in the periplaque
white matter (pattern IV). A recent case study provided evidence for
intraindividual homogeneity by demonstrating an identical immune
pattern in two different lesions of a single MS patient over time [26].
The concept of heterogeneity is supported by imaging data suggesting
that, in line with pathological ﬁndings, pattern III patients showdiffuse, not well-delineated lesions in contrast to pattern I and II
patients, where lesions are clearly demarcated and often highlighted
by ring-shaped contrast enhancement [27,28]. Furthermore, patients
with pattern II pathology respond to plasmapheresis, whereas
patients displaying the apoptosis-dominated pattern III or the T cell-
mediated pattern I do not show any response [29]. More evidence for
this concept comes from antigen microarray analysis of MS sera
demonstrating unique antibody patterns to lipids and CNS-derived
peptides that were mostly associated with MS pattern I or II [30]. The
pathological subtypes of MS do not segregate with the clinical
evolution of the disease, such as the primary progressive or secondary
progressive vs. the relapsing–remitting variant [31]. Currently, an
intense search for imaging, serum, and CSF surrogate markers for the
pathological MS heterogeneity is under way.
An alternative hypothesis brought forward by Prineas and Barnett
proposes the concept of a stage-dependent heterogeneity in MS
whereby oligodendrocyte apoptosis is thought to precede the
formation of all MS lesions and to be present before an opening of
the blood-brain barrier [17]. It is currently a matter of debate whether
T cell inﬁltration follows the demise of the myelin-forming cells in
these cases [32].
A further hypothesis is the concept of homogeneity suggesting that
only one general mechanism of demyelination, which involves
antibody- and complement-mediated myelin phagocytosis, plays a
role in patients with established MS [33]. However, it is important to
note that the lesions studied by the different groups [17,33] differed
histologically with regard to their demyelinating activity [6].
Therefore, it remains currently difﬁcult to draw ﬁnal conclusions on
the heterogeneous and homogenous aspects of MS pathology.
2.4. Normal appearing white matter
Although demyelination as hallmark of MS is largely restricted to
focal lesions, other aspects of pathology are less conﬁned. Perivascular
and also scattered parenchymal T cell inﬁltration and microglia
activation are widespread in many MS patients, even in the chronic
disease phase [34]. In addition, the effects of local demyelination and
axonal damage extend into the normal appearing white matter,
especially with anterograde (Wallerian) and retrograde degeneration
resulting in reduced axonal density and neuronal atrophy or loss in
areas far away from the original lesion site.
3. Structural damage to axons and neurons
3.1. Axonal damage and loss in white matter lesions
Histopathological evidence for acute axonal damage, as deter-
mined by visualization of disturbed axonal transport, occurs very
early in MS lesions and is most pronounced in the stage of active
demyelination [25]. The detection of diffuse axonal injury (DAI) after
brain trauma relies on the use of markers such as APP and
synaptophysin, which accumulate as a result of immediate axonal
damage, and persist for about 20–30 days [35]. Although part of the
accumulation of APP may be reversible, the abundant large axonal
spheroids most likely reﬂect irreversible axonal transections [23]. The
loss of myelin greatly enhances the propensity of axons for transport
disturbance [36]. On the one hand, non-speciﬁc immune mediators,
e.g. nitric oxide (NO), reactive oxygen species (ROS), and proteases
lead to damage of naked and also myelinated axons as indicated by
experimental studies [37,38]. On the other hand, neuronal antigens
have recently been identiﬁed as targets of the immune reaction.
Speciﬁc immune reactions against neuroﬁlament, beta-synuclein,
contactin-2/TAG-1, and neurofascin lead to CNS inﬂammation [39–
43]. Importantly, anti-neurofascin antibodies have been identiﬁed in a
proportion of MS patients and these antibodies have been shown to
aggravate axonal damage and clinical disease in the EAE model [41].
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experimental immunization with neuronal antigens.
In chronic MS lesions, axonal damage continues at a markedly
slower pace. However, APP-positive axonal proﬁles may be relatively
abundant at the edge of slowly expanding lesions [16]. Recent studies
have highlighted the importance of energy supply for axonal
maintenance, and mitochondrial abnormalities have been identiﬁed
in MS lesions [44–46]. Importantly, axonal densities are markedly
reduced in chronic MS lesions in the majority of patients and can
attain average densities of 20–30% compared to control white matter
[47]. A recent study correlating clinical and pathological ﬁndings
clearly provides evidence that the loss of corticospinal axons is the
pathological substrate of motor disability in MS [48]. How and when
does this enormous axon destruction take place? The mechanisms of
axonal loss are most likely multifaceted, ranging from the numerically
important axonal loss in the acute inﬂammatory demyelinating stage
of lesion formation to axonal damage accumulating by ongoing
disease activity. Furthermore, anterograde and retrograde degenera-
tion as a result of other, more distant lesions certainly impact on
lesional axonal densities. The clinical importance of the “slow-
burning”, but long-lasting axonal demise caused by enhanced axonal
vulnerability as a result of demyelination and/or continuous low
grade inﬂammatory damage is hard to determine, but may well
correlate with the insidious clinical worsening observed in the
progressive disease phase [49].
3.2. MS lesions of the gray matter
Largely overlooked for the last decades, demyelinated lesions of
the gray matter are now known to cover substantial areas of cortical,
deep, and spinal gray matter, mostly in chronic MS patients [50].
Subpial cortical demyelination may extend over several gyri and sulci,
whereas intracortical lesions are mostly small and inconspicuous
[5,51]. Leukocortical lesions characterized by a substantial white
matter lesion part, are mostly more inﬂammatory and show more
microglial and astroglial activation than subpial or intracortical
lesions [52]. Quantitatively, subpial lesions are the most extensive
and cover up to 70% of the cortical area in some patients [53]. Gray
matter and especially subpial and intracortical lesions are difﬁcult to
detect in vivo by MR imaging, which hampers the correlation with
speciﬁc clinical symptoms. However, ﬁrst imaging evidence suggests
that cortical lesions may contribute to cognitive deﬁcits [54,55] and
epileptic seizures [56]. The impaired visibility in standardMR imaging
can largely be explained by gray matter anatomy and the location of
cortical lesions close to the cerebrospinal ﬂuid (CSF) on the one hand
and the speciﬁc aspects of gray matter lesion pathology on the other:
Myelin density in gray matter areas is low compared to the white
matter, and partial volume effects pose a challenge to cortical signal
alterations. Cortical, and especially subpial and intracortical MS
lesions, in addition, are characterized by little inﬂammatory inﬁltra-
tion, little evidence for plasma protein extravasation, little microglia
activation and often only mild astrogliosis [57,58].
Apart from their so far-debated clinical signiﬁcance, cortical
lesions may give us hints towards the pathophysiology of MS,
whereby they suggest – together with periventricular lesions – a
role for factors diffusing from the CSF. Recent microarray studies
revealed a massive upregulation of immunoglobulin-related genes in
cortical MS sections harbouring meningeal plasma cells [59].
Furthermore, meningeal B cell aggregates have been associated with
the extent of cortical lesions and dendritic damage [60]. Other groups,
however, have not observed any association between meningeal
inﬂammation and cortical demyelinated lesions, at least in the chronic
disease phase [61]. The presence of a similar extent of cortical gray
matter lesions in primary and secondary progressive MS suggests
similar pathological mechanisms operating in both diseases [34]. Of
note, in PML patients, where demyelination is induced by thegliotropic JC virus, no subpial but only leuko- and intracortical lesions
are observed [62]. No correlation of the extent of cortical lesion load
with white matter lesions has been observed [34], suggesting that
cortical lesions are more than just a secondary, degenerative
phenomenon induced by focal white matter lesions. Nevertheless,
cortical transcripts are biased towards excitotoxicity also in normal
appearing myelinated MS cortex [44]. Furthermore, a down-regula-
tion of mitochondrial proteins and upregulation of the neuroprotec-
tive CNTF pathway was observed to be in line with the notion that
cortical damage in MS is the result of both direct local and indirect,
more distant effects [44].
In experimental models, spontaneous demyelinated cortical
lesions have been reported after immunization with MOG protein,
especially in the common marmoset and in congenic Lewis rats
bearing certain MHC I and II alleles [63–65]. Standardized procedures
to induce cortical lesions in rats have been developed, relying on the
presence of demyelinating anti-MOG antibodies and local opening of
the cortical blood-brain barrier. There, inﬂammation in the gray
matter resolves quickly, and, with certain similarities to human
cortical lesions, repair is rapid and highly successful [66,67].
3.3. Neuronal damage and loss
Neuronal damage occurs early in MS, as suggested by patholog-
ical and spectroscopic studies [2,68]. In addition to retrograde
degeneration with ensuing neuronal atrophy and death, neurons
may be directly damaged by inﬂammatory cells and mediators,
when inﬂammatory demyelinated lesions are located in the gray
matter [68].
In the spinal cord, the extent of motor neuronal loss observed on
different levels has been reported to range between 15% and 48% of
control cases [68–70]. However, the magnitude of neuronal changes
observed at cervical, thoracic and lumbar levels differs between these
post-mortem studies. To date, it still remains controversial whether
neuronal loss in the spinal cord is partly dependent [70] or quite
independent [68] of gray matter demyelination. However, neuronal
apoptosis was only observed in the presence of inﬁltrating T cells [69]
and signs of early neuronal injury also appeared more prevalent in
early MS lesions involving the anterior horn [68]. The latter study
suggests that neuronal loss occurs early but is not progressive during
disease evolution. Interestingly, the overall reductions of motor
neuronal densities [68,70] are of a magnitude similar to the mean
axonal loss of 31% in the corticospinal tract inMS [71]. Taken together,
these ﬁndings of the spinal motor system emphasize that direct-
inﬂammatory effects within lesions – and indirect retrograde
degeneration due to axonal loss – contribute to motor neuronal loss
in MS.
Similar mean reductions of neuronal densities in MS have been
observed in other gray matter areas such as the thalamus (−35%),
non-lesional caudate nucleus (−33%) as well as the hippocampal
regions CA1 and CA2-3 (−30%) [72–74]. Within the deep gray matter
more pronounced neuronal loss was observed in lesional than non-
lesional areas [73] indicating that both factors – direct inﬂammation-
related and indirect retrograde degeneration of neurons – play a role
in neuronal damage and demise in MS.
The neuronal changes in the MS neocortex are smaller than in the
spinal and deep gray matter. Neuronal numbers in leukocortical MS
lesions were only found to be reduced by approximately 10%, but
synaptic loss was more pronounced and added up to 47% [75].
Synaptic densities in upper cortical layers of subpial cortical lesions
seem to be less affected [76]. In addition, cortical lesions have been
reported to display a reduced expression of excitatory amino acid
transporters [77], indicating that excitotoxic mechanisms may play a
role in the pathogenesis of cortical demyelination.
Reactive oxygen and nitrogen species, which induce axonal and
neuronal injury by impairing mitochondrial function, thus leading to
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neuronal damage in MS lesions [44,45,78].
More insight on direct and indirect mechanisms of neuronal
damage during the acute disease phase comes from experimental
acute encephalomyelitis (EAE), the animal model of MS [79,80].
Recent experimental data provide evidence for direct-inﬂamma-
tion-mediated— neuronal damage in the spinal cord of EAE rodents.
Lower motor neuron loss ranging from 47% to 74% was observed in
different EAE models [69], whereby these changes could already be
detected early in the pre-relapse (pre-disease) phase and were
found to be already completed in the relapse phase. This study
suggests that T cells directly induce neuronal apoptosis by expres-
sing the cell death mediator TRAIL. Recently, another study showed
that CD8-positive T cells targeted against oligodendrocytes via
transgenic expression of ovalbumin-induced signiﬁcant simulta-
neous oligodendroglial and neuronal apoptosis in both hippocampal
and neocortical gray matter, whereby the ratio of apoptotic
oligodendrocytes to neurons was 3:1 [81].
More evidence for indirect mechanisms of neuronal damage
comes from a recent study reporting hippocampal neuronal loss in
EAE mice with mainly spinal pathology [82]. Decreased CA1 volumes
and loss of GABAergic interneurons were observed in the presence of
chronic microglial activation, accompanied by little inﬂammatory
inﬁltrates. Another study in rats with EAE observed cholinergic
neuronal degeneration in the hippocampus, which might be related
to peroxidase-dependant generation of nitric oxide and oxidative
stress [83].
In conclusion, direct and indirect mechanisms seem to play a role in
neuronal damage in multiple sclerosis and EAE. This is also illustrated
by a recent study in the EAE marmoset model that closely resembles
the human disease. This study found evidence of diffuse axonal and
synaptic damage within the myelinated cortex and additional axonal,
oligodendroglial and neuronal loss in demyelinated cortical lesions
[84]. Changes in the normal appearing cortex have been shown in MS,
whereby a down-regulation of GABAergic transmission as well as
mitochondrial proteins and an upregulation of the neuroprotective
CNTF pathway was observed in microarray studies [44,85].
4. The progressive disease phase
After a mean disease duration of ten years of relapsing–remitting
disease, most patients experience secondary progression — charac-
terized by insidious, non-relapse-related progression, and poor
response to immunomodulatory treatments. The seemingly non-
inﬂammatory (by MRI) nature of this therapeutically frustrating
disease phase has stimulated the concept that neurodegeneration, by
deﬁnition a relentless process of death and decay of neural structures,
may be the reason [86,87]. Pathologically however, inﬂammation and
demyelination are still important features of this disease phase [9,14].
Accordingly, diffuse inﬁltration of the white matter with T cells,
microglia activation and disturbance of axonal transport has been
reported [34]. To explain the seeming non-responsiveness of this
inﬂammation, the idea of an inﬂammation that is trapped behind a
closed blood-brain barrier - and thus not easily accessible to drugs and
not visualized by MRI - has been developed [49]. In addition, the
presence of chronic active, slowly expanding lesions has been related
to disease progression, also accompanied by T cell inﬁltration,
demyelination, and ongoing axonal damage [14]. By using immuno-
ﬂuorescent and confocal microscopy, evidence of leakage at the
endothelial tight junctions of brain microvessels has been reported
not only in lesions, but also in the normal appearing white and gray
matter in primary and secondary progressive MS which suggests
widespread and persistent leakage of the blood-brain barrier in the
progressive stage [88]. As cortical demyelination is often extensive in
patients with long disease duration [34], it has also been suggested
that this feature contributes to symptoms observed in late stagedisease. As such, there is so far little evidence that axonal damage and
loss occur independent of an adaptive immune response, also in late
disease stages [9]. The ever burning question of why this inﬂamma-
tion seems so resistant to therapy – in addition to the above concept
that assumes altered characteristics of the blood-brain barrier –might
be answered by the fact that disease accumulation is very slow,
preventing the effect of anti-inﬂammatory drugs being seen on a short
time scale (G. Comi, personal communication). Axonal damage and
loss clinically presenting as neurodegeneration might be more related
to the effect of multiple lesions along the neuraxis with ensuing
Wallerian and retrograde degeneration than an autonomous neuro-
degenerative process. Clinically, notwithstanding, a reduction by 60–
80% of axons is highly relevant and may, in the progressive disease
phase, limit the effectiveness of structural plasticity, e.g. detour
circuits around lesions [89] The notion that repair capacities may be
exhausted is well in line with large natural history studies indicating
that clinical variables only inﬂuence the ﬁrst early disease phase until
moderate disability has accumulated, whereas the secondary pro-
gressive phase is characterized by subsequent accumulation of
irreversible disability as an apparently self-perpetuating process
[90]. Also, recent data from therapeutical trials in MS using intense
immunosuppression early on suggest that the development of the
secondary progressive phase may be prevented or at least markedly
delayed, supporting the idea that CNS tissue destruction in early
disease inﬂuences the long-term outcome [91,92]. With regard to
myelin sheath repair, no difference in extent and quality has so far
been observed between patients with relapsing–remitting and
chronic (primary or secondary) progressive disease.
5. Tackling the interrelation between inﬂammation, demyelination,
and neurodegeneration
5.1. Inﬂammation and demyelination
In principle, several possible interrelations between inﬂammation,
demyelination and axonal damage can be envisaged. The most
favoured theory assumes that inﬂammation and demyelination are
closely related, and in fact that inﬂammatory mechanisms, such as
antibodies, T cells and macrophages and their products lead to
demyelination in the majority of patients. The commonly used EAE
model typically reﬂects these aspects of pathophysiology [1].
However, as discussed above, other scenarios have been developed
in which oligodendrocyte damage and myelin destruction are
considered the primary events, then followed ﬁrst by local microglia
activation and proliferation and only later by invasion of inﬂamma-
tory cells from the circulation [93,94]. In models of oligodendrocyte
impairment due to lack of essential metabolic constituents such as the
cytosolic peroxisome targeting signal type 1 receptor (PEX5), or due
to overexpression or deletion of myelin proteins, substantial axon
degeneration and also inﬂammation have been observed in addition
to the expected oligodendroglia phenotype [87,95]. In PLP-transgenic
mice, an oligoclonal CD8 T cell response has been reported with less
pathology after crossing into RAG1−/−mice with no functional T and
B lymphocytes [96,97]. Of note, however, immune reactions with
similar intensity as in MS are not regularly observed after traumatic
brain injury or stroke. Accordingly, with regard to MS pathogenesis,
an additional, strong pro-inﬂammatory stimulus or a massive local
immune-regulatory defect has to be postulated to allow for ample
invasion of blood-borne inﬂammatory cells in an initially purely
degenerative, toxic or traumatic setting.
5.2. Does early inﬂammatory-demyelination predispose to late stage
neurodegeneration?
There is ample evidence that inﬂammation is closely associated
with acute axonal injury and that demyelination further predisposes
279C. Stadelmann et al. / Biochimica et Biophysica Acta 1812 (2011) 275–282the axon to demise. The density of acutely damaged axons was found
to be higher in the early compared to the later phase of disease, most
likely indicating a change in certain axon-damaging components of
the inﬂammatory inﬁltrate [25]. Also, inﬂammatory mediators, in
this case NO, are especially toxic to demyelinated and electrically
active axons [98]. However, little is known about the effect of
chronic demyelination and low grade inﬂammation on axon
function in chronic MS. In addition, so far no experimental models
are available to test the question of whether inﬂammation or
inﬂammatory-demyelination leads to self-sustained, autonomous,
non-inﬂammatory neuronal or axonal degeneration. Cytoskeletal
abnormalities, e.g. tau hyperphosphorylation, have been reported in
chronic EAE; however, no increase in Alzheimer pathology has been
found in MS patients [99–101]. In the models of oligodendroglial
dysfunction mentioned above, axonal damage is a frequent ﬁnding
in animals at an advanced age. However, the detailed relationships
between oligodendroglial demise or malfunction, inﬂammation and
axon degeneration are still being worked out [87]. So far, in patients
the clear pathological correlate for the clinically suggested progres-
sive neurodegeneration is lacking. However, single APP-positive
spheroids indicating transected axons are found in chronic lesions,
and might – despite their low density – sufﬁce to markedly reduce
axonal densities given that this process evolves over years [9].
5.3. Axonal damage and loss in the white matter independent of focal
lesions — insight from imaging studies
Early focal inﬂammatory demyelinating lesions clearly harbor a lot
of transected axons that potentially lead to anterograde and
retrograde degeneration and corresponding changes in the white
matter. In addition, diffuse, non-focal inﬂammation in the white
matter which is not associated with demyelination but with signs of
axonal injury has been reported [34]. Is there evidence for non-
lesional axonal demise in imaging studies, suggestive of self-
autonomous, non-inﬂammatory neuronal and axonal degeneration?
As expected, a clear relationship between axonal density in the
normal appearing corpus callosum and the cerebral hemisphere white
matter lesion load was found, highly suggestive of Wallerian
degeneration [102]. Also the extent of focal inﬂammation, as reﬂected
by gadolinium-enhancing lesions, has been shown to be related to
subsequent brain atrophy, providing evidence for a cascade of
potentially irreversible tissue damage that may follow inﬂammation
and result in loss of brain parenchyma [103,104]. Axonal transections
occur at their highest densities in these focal regions of inﬂammatory-
demyelination. In contrast, a loss of NAA is observed by MR
spectroscopy already very early in MS, also in patients with very
few lesions [2]. This has been brought forward to support the concept
of a primary role of neurodegeneration in MS, and points at least to
very early changes in neuroaxonal structures in inﬂammatory
demyelinating disease. Another spectroscopic study points to a
relationship between NAA loss in cerebral normal appearing white
matter and concurrent demyelination in lesions [105]. Recent
morphometric studies also provide evidence that distant white
matter lesions contribute to retrograde and anterograde axon
degeneration in MS. Patients with spinal cord injury in MS displayed
bilateral atrophy of the primary somatosensory cortex [106]. In
addition, white matter lesions in the optic radiations have been
associated with up-stream gray matter atrophy in the lateral
geniculate nucleus [107] indicating retrograde damage of the
perikarya from axonal injury in plaques. However, this study did
not ﬁnd any association between lesions in the optic pathway and
occipital cortex atrophy. This ﬁnding, together with the radiological
paradox of less evident white matter lesions combined with diffuse
axonal loss in the NAWM in primary progressive MS, highlights the
fact that it remains difﬁcult to explain the full range of ﬁndings only by
antero- and retrograde changes from focal white matter lesions.However, at least in relapsing–remitting MS, clinical studies using
highly efﬁcient immune suppression provide strong evidence for a
key role of inﬂammation – be it focal or not – leading to subsequent
inﬂammation-mediated neuroaxonal damage [91,92].
6. Autoimmune inﬂammatory demyelinating CNS diseases — the
search for the antigen
Incited by the most prominent feature of MS pathology, namely
primary demyelination of axons, the search for the target of the
immune reaction in MS was very much focussed on oligodendrocytes
and the myelin sheath, respectively. Several antigens have been
examined in detail in experimental models and MS patients,
especially myelin basic protein (MBP), proteolipid protein (PLP) and
myelin oligodendrocyte glycoprotein (MOG). Of these, MOG, given its
localization on the surface of the myelin sheath and oligodendrocyte,
and thus its accessiblity to humoral immune reactions, was the prime
candidate. Furthermore, immunization with MOG is able to mimic MS
pathology in various animal species [108]. However, an important
anti-MOG antibody response was only observed in a small proportion
of MS patients, but much more frequently in patients, especially
children, with acute disseminated encephalomyelitis (ADEM), which
is characterized by perivenous non-conﬂuent demyelination and
mostly no persistant intrathecal antibody production [109–111]. In
recent years, neuromyelitis optica (NMO or Devic's disease), a
demyelinating disease considered a spectrum variant of MS, has
emerged as a separate disease entity [4]. NMO, which is pathologically
characterized by demyelinating lesions that are in general more
destructive than MS lesions and show clear site preferences, namely
severe affection of the optic nerve and the spinal cord, has emerged as
a disease characterized by antibodies against an antigen of astrocytic
foot processes, aquaporin 4 (AQP4) [112,113]. Vascular abnormalities
and evidence for antibody-mediated pathology, such as complement,
IgG and IgM deposits as well as attraction of eosinophilic granulocytes
had been recognized already for some time [114]. Recent data indicate
that anti-AQP4 antibodies from NMO patients are able to induce
selective astrocyte death in vivo and – at higher dosage –
demyelination and axon damage [115,116]. To date, no anti-AQP4
antibodies or astrocyte depletion have been observed inMS; however,
the search for the antigen is still ongoing [117].
7. Conclusions
Although therapies and quality of life have enormously improved
over the last years, there is still a desperate need for a concept to
prevent and treat secondary progression. Current highly efﬁcient
therapies aim at nearly complete reduction of inﬂammatory cells
invading the CNS — a very efﬁcient way to reduce relapses, albeit
prone to severe side effects. With less potent immunomodulatory
agents, inﬂammation is less markedly reduced and even a few lesions
already lead to substantial axonal damage and loss. Thus, the search
for neuroprotective agents must continue to improve and expand our
arsenal against inﬂammatory CNS diseases.
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